LT3039033T - Surišantys polipeptidai, turintys mutuotą karkasą - Google Patents

Surišantys polipeptidai, turintys mutuotą karkasą

Info

Publication number
LT3039033T
LT3039033T LT14755841T LT14755841T LT3039033T LT 3039033 T LT3039033 T LT 3039033T LT 14755841 T LT14755841 T LT 14755841T LT 14755841 T LT14755841 T LT 14755841T LT 3039033 T LT3039033 T LT 3039033T
Authority
LT
Lithuania
Prior art keywords
binding polypeptides
scaffold
mutated
mutated scaffold
polypeptides
Prior art date
Application number
LT14755841T
Other languages
English (en)
Inventor
Erik Nordling
Joakim Nilsson
Patrik Strömberg
Original Assignee
Affibody Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody Ab filed Critical Affibody Ab
Publication of LT3039033T publication Critical patent/LT3039033T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047Simultaneous synthesis of different peptide species; Peptide libraries
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1044Preparation or screening of libraries displayed on scaffold proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869Methods for sequencing
    • C12Q1/6874Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845Methods of identifying protein-protein interactions in protein mixtures
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LT14755841T 2013-08-28 2014-08-28 Surišantys polipeptidai, turintys mutuotą karkasą LT3039033T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13182022 2013-08-28
PCT/EP2014/068259 WO2015028550A1 (en) 2013-08-28 2014-08-28 C5 binding polypeptides

Publications (1)

Publication Number Publication Date
LT3039033T true LT3039033T (lt) 2019-10-25

Family

ID=49034001

Family Applications (1)

Application Number Title Priority Date Filing Date
LT14755841T LT3039033T (lt) 2013-08-28 2014-08-28 Surišantys polipeptidai, turintys mutuotą karkasą

Country Status (20)

Country Link
US (2) US9982022B2 (lt)
EP (1) EP3039033B1 (lt)
JP (2) JP7138411B2 (lt)
KR (2) KR102497083B1 (lt)
CN (3) CN105473606A (lt)
AU (1) AU2014314214C1 (lt)
BR (1) BR112016003336A2 (lt)
CA (1) CA2920005C (lt)
DK (1) DK3039033T3 (lt)
ES (1) ES2742505T3 (lt)
IL (1) IL243849A0 (lt)
LT (1) LT3039033T (lt)
MX (1) MX367423B (lt)
MY (1) MY176200A (lt)
PL (1) PL3039033T3 (lt)
PT (1) PT3039033T (lt)
RU (1) RU2714156C2 (lt)
TR (1) TR201911279T4 (lt)
WO (1) WO2015028550A1 (lt)
ZA (1) ZA201600721B (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2817329T (lt) 2012-02-20 2019-04-10 Swedish Orphan Biovitrum Ab (Publ) Polipeptidai, prisijungiantys prie žmogaus komplemento c5
CN105209482B (zh) 2013-03-15 2022-04-29 阿菲博迪公司 新的多肽
SG11201602679VA (en) * 2013-08-28 2016-05-30 Swedish Orphan Biovitrum Ab Publ Stable polypeptides binding to human complement c5
EP3193930B1 (en) * 2014-09-17 2019-06-19 Affibody AB New polypeptides
EP3625265A1 (en) 2017-07-11 2020-03-25 Alexion Pharmaceuticals, Inc. Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
CN114144433A (zh) 2019-03-22 2022-03-04 反射制药有限公司 用于目标蛋白的多价d-肽化合物
US20210061861A1 (en) 2019-03-22 2021-03-04 Reflexion Pharmaceuticals, Inc. D-peptidic compounds for vegf
WO2021089695A1 (en) * 2019-11-05 2021-05-14 Affibody Ab Polypeptides
WO2022171892A1 (en) 2021-02-15 2022-08-18 Affibody Ab New her2-binding polypeptide
IL312467A (en) * 2021-11-01 2024-06-01 Ipc Res Llc Administration of C5-binding proteins

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
WO1992009633A1 (en) 1990-11-26 1992-06-11 Public Health Laboratory Service Board Immunoglobulin-binding proteins and recombinant dna molecules coding therefor
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
SE9901379D0 (sv) * 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
EP3031827A1 (en) 2000-10-10 2016-06-15 Genentech, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
MXPA04001301A (es) 2001-08-17 2004-07-08 Tanox Inc Inhibidores de la ruta del complemento que se unen a c5 y c5a son evitar la formacion de c5b.
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
CA2579635A1 (en) 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
SE0400274D0 (sv) 2004-02-09 2004-02-09 Affibody Ab New polypeptide
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
WO2009016043A2 (en) 2007-07-31 2009-02-05 Affibody Ab New albumin binding compositions, methods and uses
DK2231860T3 (da) 2007-12-19 2011-12-05 Affibody Ab Polypeptid afledt protein A og i stand til at binde PDGF
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2077272A1 (en) * 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
EP2072525A1 (en) * 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
CN102170906B (zh) 2008-08-05 2014-07-30 诺华股份有限公司 靶定补体蛋白c5的抗体的组合物和方法
JP5960598B2 (ja) 2009-11-04 2016-08-02 アフィボディ・アーベー Her3結合ポリペプチド
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
US9211344B2 (en) 2010-07-09 2015-12-15 Affibody Ab Polypeptides
CN103228328A (zh) * 2010-11-29 2013-07-31 通用电气健康护理生物科学股份公司 亲和色谱基质
CN102127554B (zh) 2010-12-22 2012-07-25 南京农业大学 一种日本脑炎颗粒疫苗及其制备方法和应用
US9005992B2 (en) 2011-03-18 2015-04-14 Postech Academy-Industry Foundation Immobilizing fusion protein for effective and oriented immobilization of antibody on surfaces
LT2817329T (lt) 2012-02-20 2019-04-10 Swedish Orphan Biovitrum Ab (Publ) Polipeptidai, prisijungiantys prie žmogaus komplemento c5
JP5980104B2 (ja) 2012-11-22 2016-08-31 三菱電機株式会社 液晶表示装置の製造方法および液晶表示装置の製造システム
US9957330B2 (en) 2012-12-19 2018-05-01 Affibody Ab Polypeptides
SG11201602679VA (en) * 2013-08-28 2016-05-30 Swedish Orphan Biovitrum Ab Publ Stable polypeptides binding to human complement c5

Also Published As

Publication number Publication date
AU2014314214A1 (en) 2016-03-03
CN117964710A (zh) 2024-05-03
RU2016108976A (ru) 2017-10-04
AU2014314214C1 (en) 2019-01-24
KR102497083B1 (ko) 2023-02-07
RU2016108976A3 (lt) 2018-04-26
PT3039033T (pt) 2019-09-06
DK3039033T3 (da) 2019-08-26
ES2742505T3 (es) 2020-02-14
CN116987154A (zh) 2023-11-03
JP7138411B2 (ja) 2022-09-16
EP3039033B1 (en) 2019-06-19
CA2920005A1 (en) 2015-03-05
JP2020180133A (ja) 2020-11-05
AU2014314214B2 (en) 2018-07-12
US20160200772A1 (en) 2016-07-14
WO2015028550A8 (en) 2015-05-21
MY176200A (en) 2020-07-24
IL243849A0 (en) 2016-04-21
MX2016002208A (es) 2016-06-28
PL3039033T3 (pl) 2020-01-31
RU2714156C2 (ru) 2020-02-12
TR201911279T4 (tr) 2019-08-21
MX367423B (es) 2019-08-21
KR20160068744A (ko) 2016-06-15
JP2016535061A (ja) 2016-11-10
WO2015028550A1 (en) 2015-03-05
NZ716426A (en) 2021-10-29
USRE49495E1 (en) 2023-04-18
ZA201600721B (en) 2020-05-27
CN105473606A (zh) 2016-04-06
CA2920005C (en) 2023-11-28
EP3039033A1 (en) 2016-07-06
KR20220021007A (ko) 2022-02-21
US9982022B2 (en) 2018-05-29
BR112016003336A2 (pt) 2017-11-21

Similar Documents

Publication Publication Date Title
HK1216756A1 (zh) 新的多肽
GB201311475D0 (en) Polypeptides
ZA201600721B (en) Binding polypeptides having a mutated scaffold
GB201322415D0 (en) A building block for a mechanical construction
SG11201602889TA (en) Novel polypeptides
GB201306726D0 (en) A glazing
GB201322417D0 (en) A building block for a mechanical construction
GB201317990D0 (en) A conncetor
EP3011117A4 (en) ROOF
HK1222422A1 (zh) 模板元件
GB201322409D0 (en) A building block for a mechanical construction
GB201602351D0 (en) A building structure
GB201309421D0 (en) Polypeptides
ZA201506407B (en) New polypeptides
PL3080276T3 (pl) Polipeptydy toksyczne dla owadów
GB2506261B (en) A joint
GB201300656D0 (en) Building materials
GB201303977D0 (en) Binding polypeptides
GB201318941D0 (en) Novel polypeptides
GB2516914B (en) Tile
GB201311648D0 (en) A novel glass-lonomer cement
AU350587S (en) A batten
GB201403306D0 (en) Binding Polypeptides
GB201319398D0 (en) A footgauge
GB201316475D0 (en) A construction kit